Nkarta (NKTX) said Friday it appointed Shawn Rose as chief medical officer, effective June 23.
He will succeed David Shook, who is stepping down to pursue other opportunities in oncology, the company said.
The company added that during the transition, Rose will work with Shook, who will be a consultant through July 11.
Rose was most recently chief development officer, immunology, at Vividion Therapeutics, Nkarta said.
The company's shares rose 3% in recent trading.
Price: 1.89, Change: +0.05, Percent Change: +3.01
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.